BC
ANIP icon

Bridgefront Capital’s ANI Pharmaceuticals ANIP Stock Holding History

Bridgefront Capital’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,711
Closed -$372K – 521
2025
Q4 		$372K Buy
+4,711
New +$408K 0.09% 330
2025
Q1 		– Sell
-3,692
Closed -$204K – 610
2024
Q4 		$204K Buy
+3,692
New +$212K 0.07% 490

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.72B AUM 1.39% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Bridgefront Capital's ANIP Position: Q1 2026 in Review

Bridgefront Capital sold out of ANI Pharmaceuticals (ANIP) in Q1 2026, closing a stake of 4,711 shares — an estimated $372K sold.

Bridgefront Capital first reported a position in ANIP in Q4 2024 and held it in 2 quarters. The position peaked at $372K in Q4 2025. 281 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Bridgefront Capital reported no remaining ANI Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Bridgefront Capital sold 4,711 ANI Pharmaceuticals shares in Q1 2026, an estimated $372K.
  • Bridgefront Capital first reported a position in ANI Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Bridgefront Capital's ANI Pharmaceuticals position peaked at $372K in Q4 2025.
  • 281 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.